Abstract

SANCHEZ-VILLALOBOS, Oswaldo et al. Savings in the Health System due to the Direct Regulation of the Sale Prices of Biotechnological Medicines in Colombia. Rev. Gerenc. Polit. Salud [online]. 2016, vol.15, n.31, pp.120-128. ISSN 1657-7027.  https://doi.org/10.11144/Javeriana.rgyps15-31.assr.

We developed a retrospective analysis on the sales of thirteen biotechnological regulated medicines between June, 2010, and June, 2014, in two scenarios: amounts billed after the price and assumed value regulation, calculated based on the average sale price during the six months prior to the regulation, plus the health consumer price index. The difference between both scenarios entails a saving for the system. The biotechnological medicines analyzed generated savings for US $95 Million in said period; 10.2% during the first year, 17.2% during the second, and 30.5% during the third. The biotechnological medicine that generated the most savings was rituximab (40.9%), equivalent to US $38,510,787. The direct regulation of biotechnological medicines has generated significant savings for the healthcare system, as seen from the sales registered by Audifarma. Probably, the economic savings generated by this policy are above the initial government estimates.

Keywords : biotechnology; cost control; health economy; economic analysis; product marketing; medical savings.

        · abstract in Spanish | Portuguese     · text in Spanish     · Spanish ( pdf )